N-Epsilon-(carboxymethyl)lysine is unable to induce endothelial dysfunction but is able to attenuate Ages-induced endothelium damage in human umbilical vein endothelial cells. Feng L, Zhu MM, Zhang MH, et al.
Glipizide and Metformin combination is used to treat high blood sugar levels that are caused by a type of diabetes mellitus or sugar diabetes called type 2 diabetes.his process occurs during normal digestion of food. In type 2 diabetes, your body does not work properly to store the excess sugar and the sugar remains in your bloodstream. Chronic high blood sugar can lead to serious health problems in the future.
Sitagliptin is as effective as glipizide at lowering blood sugar levels in patients with type 2 diabetes and chronic kidney disease. Sitagliptin is less likely than glipizide to cause dangerously low blood sugar levels. Patients on sitagliptin tend to lose weight, while those on glipizide gain weight. Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease (CKD). Previous research indicates that the diabetes drugs sitagliptin and glipizide may not cause considerable kidney damage. New clinical trial results presented during the American Society of Nephrology's Annual Kidney Week compared the two drugs.